GLG News by Physicians who Specialize in Alcohol Withdrawal
Request a free trial
June 2, 2008
A Very Promising Approach to ADHD but Initial Claims and Monitoring Will Be Important in Success
Analysis of: Abbott Scientists Present A New Approach for Treating Attention-Deficit Hyperactivity Disorder | biz.yahoo.com
Author: GLG Expert Contributor
Analysis of: Abbott Scientists Present A New Approach for Treating Attention-Deficit Hyperactivity Disorder | biz.yahoo.com
Author: GLG Expert Contributor
Manipulation of the nicotinic receptor is a novel way to treat ADHD which has significant potential to modify the symptoms of this disorder and to enhance learning and memory. We have had some difficulty with side effects of varenicline which is a nicotinic partial agonist used in smoking cessation...
April 7, 2008
Taranabant--To Be or Not To Be
Analysis of: Taranabant looks promising | www.taranabant-health.com
Author: GLG Expert Contributor
Analysis of: Taranabant looks promising | www.taranabant-health.com
Author: GLG Expert Contributor
Although the concept is exciting--an inverse agonist at the cannabinoid-1 (CB-1) receptor to reduce appetite, this medicine has a lot of bad press from rimonabant to overcome. The major problem with rimonabant was psychopathological reactions in patients. We do not yet know whether this...
March 5, 2008
Luvox CR Approved for OCD and Social Anxiety--Where's the Beef?
Analysis of: FDA Approves Luvox CR (Fluvoxamine Maleate) Extended-Release Capsules for the Treatment of Social Anxiety Disorder and Obsessive Compulsive Disorder | pharmalive.com
Author: GLG Expert Contributor
Analysis of: FDA Approves Luvox CR (Fluvoxamine Maleate) Extended-Release Capsules for the Treatment of Social Anxiety Disorder and Obsessive Compulsive Disorder | pharmalive.com
Author: GLG Expert Contributor
Fluovoxamine is perhaps the last participant in the SSRI explosion of the 1980's. It is also the least used and hence, least profitable entry in the SSRI horse race, primarily because of timing rather than any particular pharmacological deficiency. To believe that this attempt to rejuvenate...
March 3, 2008
More non-specific treatment for smoking
Analysis of: Evotec Starts Phase II in Smoking Cessation with EVT 302 | www.pipelinereview.com
Author: GLG Expert Contributor
Analysis of: Evotec Starts Phase II in Smoking Cessation with EVT 302 | www.pipelinereview.com
Author: GLG Expert Contributor
Smoking cigarettes is a serious health problem throughout the world and smoking cessation is an important clinical problem. Stopping smoking is tremendously difficult for some because of the highly addictive nature of nicotine, but also because of the predominant use of smoking as a form of self-medication...
February 29, 2008
Antidepressants are (not) useless
Analysis of: British Study Says Anti-Depressants Are Useless | www.furiousseasons.com
Author: GLG Expert Contributor
Analysis of: British Study Says Anti-Depressants Are Useless | www.furiousseasons.com
Author: GLG Expert Contributor
I believe publications such as these are probably useful reactions to over-prescribing antidepressants for anything that ails you (which is what has been occuring until the recent suicide scare in adolescents). Nevertheless, such generalizations have significant influence even though they are...
February 25, 2008
Dementia: the same treatment regardless of the age of onset?
Analysis of: Memory Pharmaceuticals & Roche Expand Development Program for MEM 3454 in Schizophrenia | www.pipelinereview.com
Author: GLG Expert Contributor
Analysis of: Memory Pharmaceuticals & Roche Expand Development Program for MEM 3454 in Schizophrenia | www.pipelinereview.com
Author: GLG Expert Contributor
The focus of Memory Pharmaceuticals & Roche Expansion of their Development Program for MEM 3454 in schizophrenia is symptomatic of a trend in schizophrenia research that has identified cognitive deficits as the fundamental abnormality in brain functioning. It is an eminently reasonable...
February 11, 2008
Zyprexa® Long-Acting Injection (LAI): Far from a Slam-Dunk
Analysis of: FDA Advisory Committee Supports Efficacy and Safety of Zyprexa | www.fiercebiotech.com
Author: GLG Expert Contributor
Analysis of: FDA Advisory Committee Supports Efficacy and Safety of Zyprexa | www.fiercebiotech.com
Author: GLG Expert Contributor
Long-acting neuroleptics are extremely beneficial in treatment of non-compliant chronically mentally ill because it allows more medical oversight and assurance of compliance with pharmacotherapy. Olanzapine is a particularly bad atypical (new generation) neuroleptic when it comes to weight gain...
February 5, 2008
Chantix--too good to be true
Analysis of: Chantix And Suicide: The Latest Numbers | www.pharmalot.com
Author: GLG Expert Contributor
Analysis of: Chantix And Suicide: The Latest Numbers | www.pharmalot.com
Author: GLG Expert Contributor
When varenicline (Chantix) first became available for use in patients, I was incredibly impressed by how effective it was. I had one patient who was so addicted to cigarette smoking that he could not sleep through the night without a smoke--he would awake every hour or two and then go back to...
February 5, 2008
Doxepin is new again
Analysis of: Somaxon Pharmaceuticals Submits New Drug Application For SILENOR(TM) For The Treatment Of Insomnia | www.pipelinereview.com
Author: GLG Expert Contributor
Analysis of: Somaxon Pharmaceuticals Submits New Drug Application For SILENOR(TM) For The Treatment Of Insomnia | www.pipelinereview.com
Author: GLG Expert Contributor
Doxepin was developed as an antidepressant nearly 40 years ago. It has been used by generations of psychiatrists for its sedating and sleep promoting actions, much as many other of the sedating antidepressants of yore. Now it is being developed as a treatment of insomnia--the one twist is...
January 23, 2008
Novel Antidepressant Agent Tyrima(TM) has Real Potential But Efficacy Not Fully Evaluated
Analysis of: CeNeRx BioPharma Announces Successful Completion of Phase l Clinical Program for Novel Antidepressant Agent Tyrima(TM) | www.pipelinereview.com
Author: GLG Expert Contributor
Analysis of: CeNeRx BioPharma Announces Successful Completion of Phase l Clinical Program for Novel Antidepressant Agent Tyrima(TM) | www.pipelinereview.com
Author: GLG Expert Contributor
MAOI's really work very well in patients in whom tricyclic and newer and safer variations of the theme (blockade of norepinephrine, serotonin, and dopamine uptake) do not. It is about time that the focus has shifted to a safer version of MAOIs, the selective and reversible novel class of drugs...
Page : 1 2 3 4 5 6 7 8 9 10 Next1 to 10 of 132
More GLG News in
Healthcare
Most Popular:
Source Article | Expert Analyses
Use of Antipsychotics in Children Is Criticized
www.nytimes.com
Scientists recommend 'black box' for Avastin
www.fiercepharma.com
Are Costly Diabetes Pills Doing Any Good?
www.pharmalot.com
How a Drug Maker Tries to Outwit Generics
online.wsj.com
Use of Antipsychotics in Children Poses Risks of Adverse Effects
November 26, 2008
Avastin and clots? News to me. Black box warning? Why?
November 24, 2008
Off Label Use Can Be Prevented
November 24, 2008
Gardasil will most certainly be approved for boys
November 24, 2008
Medivations's (MDVN) Dimebon - We've Seen This Movie Before
November 24, 2008

